Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with Cosentyx TM after three years[1] 6 out of 10 patients (64%) had clear or ...

The label update includes 52-week data from the CLEAR study which demonstrated the long-term superiority of Cosentyx over Johnson & Johnson's JNJ Stelara (ustekinumab) in psoriasis. The study ...

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 ... modified 2011 score of ‘clear’ or ‘almost clear’ (0 or 1) with at least a ...

In addition, a larger percentage of patients in the Cosentyx group achieved an IGA (Investigator’s Global Assessment) scalp only score of 0 or 1 (clear or almost clear) vs the placebo group (56. ...

CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx (TM) compared to Stelara ® at Week 16[1] Cosentyx showed greater ...

In the GESTURE trial, 59 percent and 53 percent of palmoplantar psoriasis patients who received Cosentyx 300mg and 150mg respectively achieved clear or almost clear palms and soles at 2.5 years. In ...

The findings follow data published last year showed that Cosentyx (secukinumab) delivered almost clear or completely clear skin in a majority of patients (PASI 90 – 66 percent, PASI 100 – 44 percent) ...

76% for Cosentyx vs 61% for Stelara at 52 weeks. This head-to-head CLEAR study was published in advance of the EADV congress in the Journal of the American Academy of Dermatology. Further data ...

In the case of EXCEED the comparator will be Humira itself, while in SURPASS Cosentyx will go up against a biosimilar version of adalimumab developed by Novartis’ subsidiary Sandoz. The intention ...

Analysis from the fourth annual update of Market Dynamix™: Hidradenitis Suppurativa reveals that while it is still early post-launch, prescribers are showing a clear affinity for Cosentyx ...

- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16 ...

In this extension study, 320 patients received Cosentyx in a fixed dosing schedule for three years. 69% achieved clear or almost clear skin (PASI 90) at year one. This response was extremely well ...